21 min listen
EpicentRx Hopes Rocket-Fuel-Derived Drug Will Propel It
FromThe Bio Report
ratings:
Length:
24 minutes
Released:
Jul 18, 2019
Format:
Podcast episode
Description
Much has been made about a cancer moonshot, but in the world of oncology, rocket fuel is rarely a topic of conversation except maybe as a metaphor. EpicentRx, though, is looking to rocket fuel as a source for its lead experimental therapy RRx-001. It believes this high-energy molecule, derived from rocket fuel, has the potential to improve immunotherapies and radiotherapies, as well as having anticancer activity on its own. We spoke to Corey Carter, president and CEO of EpicentRx about how RRx-001 came about, how it works, and the company’s oncolytic viral pipeline also in development.
Released:
Jul 18, 2019
Format:
Podcast episode
Titles in the series (100)
The Forces Bringing Disruptive Change to Healthcare: Scientific breakthroughs, innovations in technology, and the changing use of data are among the forces that are driving disruptive changes to healthcare. A new report from the IMS Institute for Healthcare Informatics highlights a number of these deve... by The Bio Report